Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvotech Hits Back Over Humira Trade Secrets Accusations

AbbVie Claims Former Employee Took Adalimumab Secrets To Alvotech

Executive Summary

Alvotech has issued a robust rebuttal of accusations that it obtained AbbVie trade secrets relating to Humira for use in developing its biosimilar adalimumab rival.

You may also be interested in...



AbbVie Humira Lawsuit Withstands Alvotech Attack

Alvotech has failed in an attempt to dismiss US litigation initiated by AbbVie over Alvotech’s AVT02 proposed rival to higher-strength Humira. The company is expecting an FDA decision on the adalimumab biosimilar this month.

AbbVie Sues Alvotech Again Alleging At-Risk Adalimumab Launch

In the latest twist in the tussle between Alvotech and AbbVie over Humira intellectual property, the originator has sued the Icelandic firm for a second time in a court in Illinois, in an attempt to enforce almost 60 patents that it says Alvotech has previously declined to litigate.

FTC Urged To Investigate AbbVie’s IP Strategy On Humira

AbbVie delayed biosimilar competition to Humira “for far longer than warranted” and may have “engaged in other anti-competitive conduct to maintain its market share and pricing power” for the adalimumab brand, according to members of the US House of Representatives’ committee on oversight and reform. The US Federal Trade Commission has been urged to open a formal inquiry into the originator’s conduct.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB150777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel